Growth Effects of Tamoxifen and Estradiol on Laryngeal Carcinoma Cell Lines
K. Thomas Robbins, MD;
Tien P. Vu, MD;
Armida Diaz;
Nissi M. Varki, MD
Arch Otolaryngol Head Neck Surg. 1994;120(11):1261-1266.
Abstract
| |
Objectives
We tested the in vitro and in vivo growth effects of estradiol and tamoxifen citrate to determine whether patients with laryngeal carcinoma could benefit from antiestrogen therapy as demonstrated for cancers of other estrogen-responsive organs.
Design
A comparison of growth effects of the hormones relative to controls by using a tetrazolium dye reduction assay and nude mice.
Materials
Two estrogen-positive laryngeal carcinoma cell lines (UMSCC5 and UMSCC11B) and athymic mice were used.
Results
There were marked growth inhibitory effects of tamoxifen alone in concentrations of 3 to 8 µmol/L on both cell lines. There were no in vitro growth effects of estradiol-17β alone in concentrations of 0.1 to 9.6 µmol/L, but there was antagonism of the estradiol to the growth inhibitory effects of tamoxifen. In athymic mice, estradiol markedly stimulated the growth of UMSCC5, whereas tamoxifen inhibited growth.
Conclusions
These results support the concept of chemotherapeutic growth inhibition of estrogen receptor—positive laryngeal cancer with antiestrogens.
(Arch Otolaryngol Head Neck Surg. 1994;120:1261-1266)
Author Affiliations
From the Department of Otolaryngology—Head and Neck Surgery, University of Tennessee, Memphis (Dr Robbins); and the Division of Hematology and Oncology, Department of Medicine, University of California—San Diego (Drs Vu and Varki and Ms Diaz).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck
Amornphimoltham et al.
Cancer Res. 2005;65:9953-9961.
ABSTRACT
| FULL TEXT
|
